Compare SGHC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGHC | KYMR |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | Guernsey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.4B |
| IPO Year | N/A | 2020 |
| Metric | SGHC | KYMR |
|---|---|---|
| Price | $9.72 | $70.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 24 |
| Target Price | $16.00 | ★ $105.35 |
| AVG Volume (30 Days) | ★ 2.0M | 682.9K |
| Earning Date | 02-24-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.60% | N/A |
| EPS Growth | ★ 4925.62 | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $2,342,912,011.00 | $43,735,000.00 |
| Revenue This Year | $28.42 | $18.70 |
| Revenue Next Year | $10.86 | N/A |
| P/E Ratio | $22.03 | ★ N/A |
| Revenue Growth | ★ 34.94 | N/A |
| 52 Week Low | $5.59 | $19.45 |
| 52 Week High | $14.38 | $103.00 |
| Indicator | SGHC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 42.58 |
| Support Level | $9.59 | $66.21 |
| Resistance Level | $10.40 | $72.86 |
| Average True Range (ATR) | 0.49 | 3.68 |
| MACD | -0.09 | -0.74 |
| Stochastic Oscillator | 6.91 | 32.12 |
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's reportable segments are Betway, Spin, and Other. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.